After the Martinsried-based start-up EpiQMAx had to file for insolvency in the third quarter of this year, the epigenetics specialist has now been acquired by the Berlin-based company MoleQlar for longevity solutions.
EpiQMax was founded in 2018 as a spin-off from Ludwig-Maximilians-Universität München (LMU) and specializes in proteome analysis and epigenetics. The company offers, for example, a saliva test that provides deeper insights into how the body functions at a cellular level.
Dr. Moritz Völker-Albert, CEO of MoleQlar Analytics GmbH, which was founded as part of the acquisition, is delighted to become part of the MoleQlar team with EpiQMax: "Our technical capabilities in proteomic analysis and histone modification quantification will significantly increase MoleQlar's clout and
help us to apply epigenetics to sustainably improve people's lives through advanced personalized health solutions."
By integrating EpiQMAx's proteomic analysis technologies, MoleQlar aims to expand its analytical and product development capabilities. "We look forward to welcoming their expert team and advanced technologies to our company", commented Maximilian Griessinger, CEO of MoleQlar.
The acquisition of EpiQMAx comes after a challenging period for the Munich-based company, which had to file for insolvency in the third quarter of 2023. EpiQMAx offers a service for the detection and quantification of proteins and epigenetic histone modifications. Since its foundation in 2020, the Berlin-based company MoleQlar has become the market leader for longevity solutions in German-speaking countries.